| HOME >> BIOLOGY >> TECHNOLOGY |
IRVINE, Calif., Nov. 15, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that it has received a Notice of Issuance for its patent application for Dissolution of Arterial Plaque. This patent issuance is the first major step in the development of the Company's intellectual property involving lipid modulation and reduction. This issuance culminates a major effort by the Company and its patent counsel in pursuit of a patent covering the use of hyodeoxycholic acid for atherosclerotic plaque lesions.
"This patent issuance is a tremendous milestone for the Company," said AtheroNova CEO Thomas W. Gardner. "We are very confident that this patent will support our development project for AHRO-001 as we move toward the next phase of entering human clinical trials. The Company's partner, OOO CardioNova, has completed a similar intellectual property filing on behalf of AtheroNova in the Eurasian markets and they expect action on these filings to be moving forward in the near future."
About AHRO-001
AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain pharmacological compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are then removed by natural body processes. AtheroNova is developing, and seeks to eventually market AHRO-001, a product that has the potential to become a new standard of care for patients prone to atherosclerotic plaque accumulation.
About AtheroNova
AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a biotechnolog
'/>"/>
| SOURCE AtheroNova Inc. Copyright©2012 PR Newswire. All rights reserved |
Related biology technology :
1. AtheroNova Names New Director
2. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
3. AtheroNova Releases 2011 Financial Results
4. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
5. AtheroNova Announces a New Board Member
6. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Ceres Receives $3.5 million from USAID for Trait Stacks
9. Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
10. Hertz Fellow, Grant I. Gillary, Receives Hertz Foundation-George Lerman Fellowship
11. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |